Phio Pharmaceuticals (NASDAQ:PHIO) Director Acquires $15,189.00 in Stock

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) Director Ronald Plott purchased 18,300 shares of the business’s stock in a transaction dated Monday, November 9th. The shares were purchased at an average price of $0.83 per share, with a total value of $15,189.00. Following the acquisition, the director directly owned 60,300 shares in the company, valued at approximately $50,049. The trade was a 43.57% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Ronald Todd Plott also recently made the following trade(s):

• On Monday, September 28th, Ronald Plott acquired 5,000 shares of Phio Pharmaceuticals stock. The stock was acquired at an average price of $1.03 per share, for a total transaction of $5,150.00.
• On Wednesday, August 19th, Ronald Plott acquired 15,000 shares of Phio Pharmaceuticals stock. The stock was acquired at an average price of $1.14 per share, for a total transaction of $17,100.00.

Phio Pharmaceuticals Trading Down 0.2%

Shares of Phio Pharmaceuticals stock opened at $0.81 on Friday. Phio Pharmaceuticals Corp. has a fifty-two week low of $0.75 and a fifty-two week high of $1.88. The stock has a 50 day moving average of $0.95 and a 200 day moving average of $1.08.

Phio Pharmaceuticals (NASDAQ:PHIO) last posted its earnings results on Thursday, November 5th. The company reported ($0.36) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.36). Research analysts predict that Phio Pharmaceuticals Corp. will post -1.47 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on PHIO shares. HC Wainwright restated a “buy” rating on shares of Phio Pharmaceuticals in a report on Wednesday, August 26th. Weiss Ratings reissued a “sell (e+)” rating on shares of Phio Pharmaceuticals in a research note on Thursday, October 15th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $14.00.

About Phio Pharmaceuticals

Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a biotechnology company focused on developing cancer immunotherapies. The company’s programs are designed to enhance the immune system’s ability to recognize and destroy tumor cells, with an emphasis on treatments that may be administered directly to the tumor or used in combination with other therapies. Phio’s research is based on its INTASYL self-delivering RNA interference (RNAi) technology. The platform is intended to selectively silence genes involved in immune suppression and cancer progression without requiring a separate delivery vehicle.